Showing 321-330 of 1560 results for "".
Strategies to Overcome Cancer Drug Resistance
https://reachmd.com/programs/focus-on-cancer/strategies-to-overcome-cancer-drug-resistance/3792/Cancer cells almost always defeat drug therapies. Can combination therapies prevent or overcome drug resistance? Join host Dr. Bruce Bloom as he discusses the research and clinical issues of cancer treatment with Dr. Jeffrey Settleman, professor of medicine at Harvard Medical School and scientific dMonitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
https://reachmd.com/programs/project-oncology/monitoring-adverse-events-post-car-t-the-latest-approaches-and-best-practices/35453/As CAR T-cell therapy advances, so does the complexity of adverse event monitoring. Due to evolving insights into acute toxicities, infections, cytopenias, and secondary malignancies, both inpatient and outpatient care models are adapting to meet new standards. Joining Dr. Charles Turck to discuss pImproved Pathogen ID in Sepsis with Clinical Metagenomic Sequencing
https://reachmd.com/programs/clinicians-roundtable/improved-pathogen-id-in-sepsis-with-clinical-metagenomic-sequencing/32854/Can clinical metagenomic sequencing of microbial cell-free DNA identify sepsis pathogens faster and more reliably than traditional blood cultures? That’s the question at the heart of the Next GeneSiS trial. The findings revealed that detected likely pathogens in over 70 percent of cases—more than trPeptide Stapling: A Novel Approach to Cancer Drug Development
https://reachmd.com/programs/clinicians-roundtable/peptide-stapling-a-novel-approach-to-cancer-drug-development/2429/Dr. Loren Walensky, Assistant Professor of Pediatric Oncology at Harvard Medical School and Medical Director of the Program of Cancer Chemical Biology at the Dana-Farber Cancer Institute discusses the biology of cell death and how a new chemical technology is yielding a host of new tools to study anDiagnosing LCNEC of the Lung: Challenges and Strategies
https://reachmd.com/programs/project-oncology/diagnosing-lcnec-of-the-lung-challenges-and-strategies/36457/Large cell neuroendocrine carcinoma (LCNEC) of the lung can pose significant diagnostic challenges due to its overlapping features with other lung cancers. Explore the pathologic hallmarks, immunohistochemical markers, and emerging molecular insights that are shaping more accurate diagnosis and targDurable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
https://reachmd.com/programs/project-oncology/durable-outcomes-in-nsclc-6-year-survival-findings-from-checkmate-9la/35998/What does long-term survival look like for patients with metastatic non-small cell lung cancer (NSCLC) treated with dual checkpoint blockade and limited chemotherapy? Dive into the data with Dr. Jacob Sands and Dr. Sandip Patel as they review the 6-year survival and response durability outcomes fromOptimizing Immunotherapy for Advanced NSCLC: How to Manage Immune Toxicities
https://reachmd.com/programs/project-oncology/optimizing-immunotherapy-for-advanced-nsclc-how-to-manage-immune-toxicities/35997/Immunotherapy is transforming the treatment of advanced non-small cell lung cancer (NSCLC), but immune-related adverse events remain a significant clinical concern. That’s why Dr. Jacob Sands speaks with Dr. Christine Bestvina about early identification, multidisciplinary collaboration, and other prExamining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
https://reachmd.com/programs/project-oncology/examining-real-world-ibrutinib-outcomes-in-rr-mcl-findings-from-a-danish-study/37209/A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstracEvaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
https://reachmd.com/programs/frontlines-non-small-cell-lung-cancer/evaluating-dato-dxd-for-egfr-mutated-advanced-nsclc-data-from-a-pooled-analysis/32940/There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According to the results, Dato-DXd demonstrDato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
https://reachmd.com/programs/project-oncology/dato-dxd-intracranial-efficacy-nsclc/36609/A recent post-hoc analysis of the TROPION-Lung01 trial—which was presented at the 2025 World Conference on Lung Cancer—sheds light on the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with advanced non-small cell lung cancer (NSCLC) and baseline brain metastases. The finding